NZ529551A - 3,4-DI-substituted cyclobutene-1,2-diones as CXC- chemokine receptor ligands - Google Patents

3,4-DI-substituted cyclobutene-1,2-diones as CXC- chemokine receptor ligands

Info

Publication number
NZ529551A
NZ529551A NZ529551A NZ52955102A NZ529551A NZ 529551 A NZ529551 A NZ 529551A NZ 529551 A NZ529551 A NZ 529551A NZ 52955102 A NZ52955102 A NZ 52955102A NZ 529551 A NZ529551 A NZ 529551A
Authority
NZ
New Zealand
Prior art keywords
compound
substituted
unsubstituted
formula
group
Prior art date
Application number
NZ529551A
Other languages
English (en)
Inventor
Arthur G Taveras
Cynthia J Aki
Richard W Bond
Jianping Chao
Michael Dwyer
Johan A Ferreira
Jianhua Chao
Younong Yu
John J Baldwin
Bernd Kaiser
Ge Li
J Robert Merritt
Kingsley H Nelson
Laura L Rokosz
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of NZ529551A publication Critical patent/NZ529551A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doublyโ€”bound oxygen atoms bound to the same carbon skeleton, at least one of the doublyโ€”bound oxygen atoms not being part of a โ€”CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doublyโ€”bound oxygen atoms bound to the same carbon skeleton, at least one of the doublyโ€”bound oxygen atoms not being part of a โ€”CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
NZ529551A 2001-04-16 2002-04-15 3,4-DI-substituted cyclobutene-1,2-diones as CXC- chemokine receptor ligands NZ529551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28402601P 2001-04-16 2001-04-16
PCT/US2002/012681 WO2002083624A1 (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Publications (1)

Publication Number Publication Date
NZ529551A true NZ529551A (en) 2006-02-24

Family

ID=23088576

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ529551A NZ529551A (en) 2001-04-16 2002-04-15 3,4-DI-substituted cyclobutene-1,2-diones as CXC- chemokine receptor ligands
NZ543869A NZ543869A (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine repcetor ligands
NZ560453A NZ560453A (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ543869A NZ543869A (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine repcetor ligands
NZ560453A NZ560453A (en) 2001-04-16 2002-04-15 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

Country Status (30)

Country Link
EP (2) EP1381590B1 (enExample)
JP (3) JP4499993B2 (enExample)
KR (2) KR100952531B1 (enExample)
CN (2) CN1289471C (enExample)
AR (1) AR035825A1 (enExample)
AT (2) ATE458715T1 (enExample)
AU (3) AU2002311841B2 (enExample)
BR (1) BRPI0208957B8 (enExample)
CA (1) CA2444031C (enExample)
CY (2) CY1109908T1 (enExample)
CZ (1) CZ20032831A3 (enExample)
DE (2) DE60220778T2 (enExample)
DK (2) DK1381590T3 (enExample)
EC (1) ECSP034809A (enExample)
ES (2) ES2287284T3 (enExample)
HU (1) HUP0401783A3 (enExample)
IL (3) IL158262A0 (enExample)
MX (1) MXPA03009441A (enExample)
MY (2) MY138202A (enExample)
NO (2) NO330790B1 (enExample)
NZ (3) NZ529551A (enExample)
PE (1) PE20021084A1 (enExample)
PL (2) PL207255B1 (enExample)
PT (2) PT1381590E (enExample)
RU (1) RU2344123C9 (enExample)
SI (2) SI1381590T1 (enExample)
SK (1) SK287598B6 (enExample)
TW (2) TWI316930B (enExample)
WO (1) WO2002083624A1 (enExample)
ZA (1) ZA200307905B (enExample)

Families Citing this family (75)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2005505595A (ja) 2001-10-12 2005-02-24 ใ‚ทใ‚งใƒผใƒชใƒณใ‚ฐใ€€ใ‚ณใƒผใƒใƒฌใ‚คใ‚ทใƒงใƒณ ๏ผฃ๏ฝ˜๏ฝƒโˆ’ใ‚ฑใƒขใ‚ซใ‚คใƒณใƒฌใ‚ปใƒ—ใ‚ฟใƒผใ‚ขใƒณใ‚ฟใ‚ดใƒ‹ใ‚นใƒˆใจใ—ใฆใฎ๏ผ“๏ผŒ๏ผ”โˆ’ไบŒ็ฝฎๆ›ใƒžใƒฌใ‚คใƒŸใƒ‰ๅŒ–ๅˆ็‰ฉ
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US6878709B2 (en) 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
CN100444839C (zh) * 2002-03-18 2008-12-24 ๅ…ˆ็ตๅ…ฌๅธ ๅผ(i)ๅŒ–ๅˆ็‰ฉๅœจๅˆถๅค‡ๆฒป็–—ๅŒ–ๅญฆๆฟ€ๆดป็‰ฉไธญไป‹็š„็–พ็—…็š„่ฏ็‰ฉไธญ็š„ๅบ”็”จ
GB0218326D0 (en) * 2002-08-07 2002-09-11 Glaxo Group Ltd Compounds
WO2004033440A1 (en) 2002-10-09 2004-04-22 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
DE502004009440D1 (de) 2003-04-03 2009-06-10 Merck Patent Gmbh Pyrrolidin-1,2-dicarbonsรคure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
JP4440917B2 (ja) * 2003-04-18 2010-03-24 ใ‚ทใ‚งใƒผใƒชใƒณใ‚ฐ ใ‚ณใƒผใƒใƒฌใ‚คใ‚ทใƒงใƒณ ๏ผ’โˆ’ใƒ’ใƒ‰ใƒญใ‚ญใ‚ทโˆ’๏ฝŽ๏ผŒ๏ฝŽโˆ’ใ‚ธใƒกใƒใƒซโˆ’๏ผ“โˆ’๏ผป๏ผป๏ผ’โˆ’๏ผˆ๏ผ‘๏ผˆ๏ฝ’๏ผ‰โˆ’๏ผ•โˆ’ใƒกใƒใƒซโˆ’๏ผ’โˆ’ใƒ•ใƒฉใƒ‹ใƒซ๏ผ‰ใƒ—ใƒญใƒ”ใƒซ๏ผฝใ‚ขใƒŸใƒŽ๏ผฝโˆ’๏ผ“๏ผŒ๏ผ”โˆ’ใ‚ธใ‚ชใ‚ญใ‚ฝโˆ’๏ผ‘โˆ’ใ‚ทใ‚ฏใƒญใƒ–ใƒ†ใƒณโˆ’๏ผ‘โˆ’ใ‚คใƒซ๏ผฝใ‚ขใƒŸใƒŽ๏ผฝใƒ™ใƒณใ‚บใ‚ขใƒŸใƒ‰ใฎๅˆๆˆ
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
GB0320983D0 (en) * 2003-09-08 2003-10-08 Biofocus Plc Compound libraries
PT1664007E (pt) 2003-09-23 2010-02-15 Fermion Oy Preparaรงรฃo de quetiapina
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ATE406356T1 (de) 2003-12-19 2008-09-15 Schering Corp Thiadiazole als cxc- und cc- chemokinrezeptorliganden
MXPA06007205A (es) 2003-12-22 2006-08-31 Schering Corp Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina.
MY144657A (en) * 2004-01-30 2011-10-31 Schering Corp Crystalline polymorphs of a cxc-chemokine receptor ligand.
EP1742914A1 (en) * 2004-02-27 2007-01-17 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
WO2006023435A1 (en) * 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
JP5149009B2 (ja) 2004-09-20 2013-02-20 ใ‚ผใƒŽใƒณใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใƒ’ใƒˆใ‚นใƒ†ใ‚ขใƒญใ‚คใƒซโˆ’๏ผฃ๏ฝ๏ผกใƒ‡ใ‚ตใƒใƒฅใƒฉใƒผใ‚ผใ‚’้˜ปๅฎณใ™ใ‚‹ใŸใ‚ใฎใƒ”ใƒชใƒ€ใ‚ธใƒณ่ช˜ๅฐŽไฝ“
AR051093A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsรคurederivate mit antiproliferativer Wirkung
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CN101253165A (zh) * 2005-06-29 2008-08-27 ๅ…ˆ็ตๅ…ฌๅธ ไฝœไธบcxc๏ผๅŒ–ๅญฆๆดป็ด ๅ—ไฝ“้…ไฝ“็š„ไบŒๅ–ไปฃ็š„๎•ทไบŒๅ”‘
JP2009500328A (ja) * 2005-06-29 2009-01-08 ใ‚ทใ‚งใƒผใƒชใƒณใ‚ฐ ใ‚ณใƒผใƒใƒฌใ‚คใ‚ทใƒงใƒณ ๏ผฃ๏ฝ˜๏ฝƒโˆ’ใ‚ฑใƒขใ‚ซใ‚คใƒณใƒฌใ‚ปใƒ—ใ‚ฟใƒผใƒชใ‚ฌใƒณใƒ‰ใจใ—ใฆใฎ๏ผ•๏ผŒ๏ผ–โˆ’ใ‚ธโˆ’็ฝฎๆ›ใ‚ชใ‚ญใ‚ตใ‚ธใ‚ขใ‚พใƒญใƒ”ใƒฉใ‚ธใƒณใŠใ‚ˆใณใƒใ‚ขใ‚ธใ‚ขใ‚พใƒญใƒ”ใƒฉใ‚ธใƒณ
DE102005035742A1 (de) * 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsรคurederivate II
RU2458051C2 (ru) * 2005-11-24 2012-08-10 ะ”ะžะœะŸะ• ะคะ.ะ .ะœะ ะก.ะฟ.ะ. (r)-ะฐั€ะธะปะฐะปะบะธะปะฐะผะธะฝะพะฟั€ะพะธะทะฒะพะดะฝั‹ะต ะธ ัะพะดะตั€ะถะฐั‰ะธะต ะธั… ั„ะฐั€ะผะฐั†ะตะฒั‚ะธั‡ะตัะบะธะต ะบะพะผะฟะพะทะธั†ะธะธ
JP5437061B2 (ja) * 2006-05-26 2014-03-12 ใ‚ขใƒƒใƒดใ‚ฃใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใƒใƒญๆง˜ใ‚ญใƒŠใƒผใ‚ผใฎ้˜ปๅฎณ่–ฌ
EP2026770A1 (en) * 2006-06-12 2009-02-25 Schering Corporation Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
EP2041107A1 (en) * 2006-07-07 2009-04-01 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
MX2009013276A (es) * 2007-06-06 2010-01-25 Novartis Ag Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
CN101932553A (zh) * 2007-07-03 2010-12-29 ๅ…ˆ็ตๅ…ฌๅธ ๅˆๆˆ1,2-ๅ–ไปฃ็š„3,4-ไบŒๆฐงไปฃ-1-็Žฏไธ็ƒฏๅŒ–ๅˆ็‰ฉ็š„ๆ–นๆณ•ๅ’Œไธญ้—ดไฝ“
EP2318369A1 (en) * 2008-06-24 2011-05-11 TopoTarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
UA103198C2 (en) 2008-08-04 2013-09-25 ะะพะฒะฐั€ั‚ะธั ะะณ Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) * 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
KR101916489B1 (ko) 2011-01-07 2018-11-07 ์•Œ๋Ÿฌ๊ฐ„, ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ ๋ฉœ๋ผ๋‹Œ ๋ณ€ํ˜• ์กฐ์„ฑ๋ฌผ๋“ค ๋ฐ ์ด์˜ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•๋“ค
PT2760821T (pt) 2011-09-02 2018-01-11 Novartis Ag Sal de colina de um composto anti-inflamatรณrio de ciclobutenodiona substituรญda
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CN103242210B (zh) * 2012-02-09 2014-09-24 ๅŒ—ไบฌ่‰พ็™พ่ฏบ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ๅซๆœ‰ๅ–ไปฃๆ–น้…ธ็š„ไน™้…ธๅฆ™ๆž—้…ฏๅŠๅ…ถๅบ”็”จ
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103382192A (zh) * 2012-05-04 2013-11-06 ๅŒๅˆ›ๅŒป่ฏ(่‹ๅทž)ๆœ‰้™ๅ…ฌๅธ N-ๅ•ๅ–ไปฃๅ“Œๅ—ช่ก็”Ÿ็‰ฉ็š„ๅˆถๅค‡
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103214327A (zh) * 2013-03-22 2013-07-24 ้ƒ‘ๅทžๆณฐๅŸบ้ธฟ่ฏบ่ฏ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็ง่Šณ้ฆ™็Žฏๆˆ–่Šณๆ‚็Žฏไธ‰ๆฐŸ็”ฒๅŸบ้…ฎๅŒ–ๅˆ็‰ฉๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kinรกz inhibitorok
TWI734715B (zh) 2015-11-19 2021-08-01 ็พŽๅ•†ๅก้ป˜ๆฃฎๅฑˆๆœ‰้™ๅ…ฌๅธ ่ถจๅŒ–ๅ› ๅญๅ—้ซ”่ชฟ็ฏ€ๅŠ‘
TWI724056B (zh) 2015-11-19 2021-04-11 ็พŽๅ•†ๅก้ป˜ๆฃฎๅฑˆๆœ‰้™ๅ…ฌๅธ ๏ผฃ๏ฝ˜๏ฝƒ๏ฝ’๏ผ’ๆŠ‘ๅˆถๅŠ‘
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle ร‰piniรจre) Prognosis of demyelinating diseases patients and treatment thereof
RU2020106383A (ru) 2017-08-14 2021-09-16 ะะปะปะตั€ะณะฐะฝ, ะ˜ะฝะบ. 3,4-ะดะฒัƒะทะฐะผะตั‰ะตะฝะฝั‹ะต 3-ั†ะธะบะปะพะฑัƒั‚ะตะฝ-1,2-ะดะธะพะฝั‹ ะธ ะธั… ะฟั€ะธะผะตะฝะตะฝะธะต
WO2019067332A1 (en) 2017-09-27 2019-04-04 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
GEP20237476B (en) 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
CN110041309B (zh) * 2019-04-04 2022-01-28 ๅนฟไธœๅทฅไธšๅคงๅญฆ ไธ€็ง2-็พงๅŸบๅ“Œๅ—ช่ฟžๆŽฅ็š„ไป–ๅ…‹ๆž—-8-ๆฐจๅŸบ(็พŸๅŸบ)ๅ–นๅ•‰่ก็”Ÿ็‰ฉๅŠๅˆถๅค‡ไธŽๅบ”็”จ
BR112022006226A2 (pt) * 2019-10-07 2022-06-28 De Shaw Res Llc Compostos heterocรญclicos de arilmetileno como bloqueadores de canal do agitador de potรกssio kv1,3
KR102710925B1 (ko) * 2021-06-01 2024-09-27 ๋ถ€์‚ฐ๋Œ€ํ•™๊ต ์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์‹ ๊ทœ ์Šคํ€˜์–ด์•„๋งˆ์ด๋“œ ์œ ๋„์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
CN118339161B (zh) * 2021-12-10 2025-12-09 ๆญฃๅคงๅคฉๆ™ด่ฏไธš้›†ๅ›ข่‚กไปฝๆœ‰้™ๅ…ฌๅธ ไธ€็งๅผ‚ๅ™ปๅ”‘ๅนถ[5,4-d]ๅ˜งๅ•ถ็ฑปIRAK4ๆŠ‘ๅˆถๅ‰‚็š„ๅˆถๅค‡ๆ–นๆณ•

Family Cites Families (18)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0692915A (ja) * 1992-07-28 1994-04-05 Sumitomo Metal Ind Ltd ๏ผ‘๏ผŒ๏ผ’โˆ’ใ‚ธใ‚ขใƒŸใƒŽใ‚ทใ‚ฏใƒญใƒ–ใƒ†ใƒณโˆ’๏ผ“๏ผŒ๏ผ”โˆ’ใ‚ธใ‚ชใƒณ่ช˜ๅฐŽไฝ“ๅŠใณใใฎ็”จ้€”
GB9312210D0 (en) * 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
ES2128774T3 (es) * 1994-11-16 1999-05-16 American Home Prod Diaminociclobuten-3,4-dionas.
HUP9903922A3 (en) * 1996-06-27 2001-12-28 Smithkline Beecham Corp Il-8 receptor antagonists
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AU6250298A (en) * 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US6211220B1 (en) * 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
BR9916211A (pt) * 1998-12-14 2001-09-11 American Home Prod Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesรฃo de leucรณcito mediada por vla-4
JP2002532465A (ja) * 1998-12-16 2002-10-02 ใƒใ‚คใ‚จใƒซ ใ‚ขใ‚ฏใƒใ‚งใƒณใ‚ฒใ‚ผใƒซใ‚ทใƒฃใƒ•ใƒˆ ใ‚คใƒณใƒ†ใ‚ฐใƒชใƒณใ‚ขใƒณใ‚ฟใ‚ดใƒ‹ใ‚นใƒˆใจใ—ใฆใฎๆ–ฐ่ฆใชใƒ“ใƒ•ใ‚งใƒ‹ใƒซๅŠใณใƒ“ใƒ•ใ‚งใƒ‹ใƒซโˆ’้กžไผผๅŒ–ๅˆ็‰ฉ
US6518283B1 (en) * 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
MXPA02011868A (es) * 2000-05-30 2003-04-10 Smithkline Beecham Corp Antagonistas de receptor de interleucina 8.
US20040048897A1 (en) * 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
KR20030088044A (ko) * 2001-03-30 2003-11-15 ์Šค๋ฏธ์Šคํด๋ผ์ธ ๋น„์ฐธ ์ฝ”ํฌ๋ ˆ์ด์…˜ ํŽ˜๋†€-ํ•จ์œ  ํ™”ํ•ฉ๋ฌผ์˜ ํ•ฉ์„ฑ ๋ฐฉ๋ฒ•
CN100444839C (zh) * 2002-03-18 2008-12-24 ๅ…ˆ็ตๅ…ฌๅธ ๅผ(i)ๅŒ–ๅˆ็‰ฉๅœจๅˆถๅค‡ๆฒป็–—ๅŒ–ๅญฆๆฟ€ๆดป็‰ฉไธญไป‹็š„็–พ็—…็š„่ฏ็‰ฉไธญ็š„ๅบ”็”จ

Also Published As

Publication number Publication date
CN1516687A (zh) 2004-07-28
CZ20032831A3 (cs) 2004-03-17
JP5294418B2 (ja) 2013-09-18
IL158262A (en) 2012-05-31
PL208928B1 (pl) 2011-06-30
JP2010053151A (ja) 2010-03-11
BRPI0208957B1 (pt) 2018-10-09
ATE458715T1 (de) 2010-03-15
PT1818325E (pt) 2010-05-12
PT1381590E (pt) 2007-08-06
CY1109989T1 (el) 2014-09-10
DK1818325T3 (da) 2010-05-31
ES2287284T3 (es) 2007-12-16
EP1818325A3 (en) 2008-02-13
JP2004532846A (ja) 2004-10-28
HK1107818A1 (en) 2008-04-18
IL201754A0 (en) 2010-06-16
TW200736196A (en) 2007-10-01
CY1109908T1 (el) 2014-09-10
SK12882003A3 (sk) 2004-06-08
MY138202A (en) 2009-05-29
EP1818325B1 (en) 2010-02-24
AU2006203679A1 (en) 2006-09-14
SI1381590T1 (sl) 2007-10-31
NO20110050L (no) 2003-12-08
TWI316930B (en) 2009-11-11
SI1818325T1 (sl) 2010-06-30
ATE365154T1 (de) 2007-07-15
RU2344123C2 (ru) 2009-01-20
EP1381590A1 (en) 2004-01-21
IL158262A0 (en) 2004-05-12
EP1381590B1 (en) 2007-06-20
ECSP034809A (es) 2004-02-26
HK1057538A1 (en) 2004-04-08
MXPA03009441A (es) 2004-02-12
DE60220778D1 (en) 2007-08-02
ES2340207T3 (es) 2010-05-31
SK287598B6 (sk) 2011-03-04
PL367129A1 (en) 2005-02-21
JP2009179641A (ja) 2009-08-13
ZA200307905B (en) 2005-03-30
DK1381590T3 (da) 2007-10-22
RU2003133448A (ru) 2005-06-10
BR0208957A (pt) 2004-06-22
HUP0401783A3 (en) 2005-06-28
CA2444031A1 (en) 2002-10-24
HUP0401783A2 (hu) 2005-01-28
JP4499993B2 (ja) 2010-07-14
NO20034612L (no) 2003-12-08
KR20030092074A (ko) 2003-12-03
NO20034612D0 (no) 2003-10-15
PE20021084A1 (es) 2002-12-20
DE60220778T2 (de) 2008-03-06
NZ560453A (en) 2009-03-31
WO2002083624A1 (en) 2002-10-24
MY149050A (en) 2013-07-15
AU2010212484A1 (en) 2010-09-09
AU2002311841B2 (en) 2006-09-14
CN1990457A (zh) 2007-07-04
RU2344123C9 (ru) 2009-05-20
CN1289471C (zh) 2006-12-13
PL207255B1 (pl) 2010-11-30
AU2010212484B2 (en) 2012-04-12
NZ543869A (en) 2007-09-28
AR035825A1 (es) 2004-07-14
CA2444031C (en) 2012-02-21
KR20100008794A (ko) 2010-01-26
NO330790B1 (no) 2011-07-18
DE60235507D1 (de) 2010-04-08
EP1818325A2 (en) 2007-08-15
BRPI0208957B8 (pt) 2021-05-25
KR100952531B1 (ko) 2010-04-12

Similar Documents

Publication Publication Date Title
NZ529551A (en) 3,4-DI-substituted cyclobutene-1,2-diones as CXC- chemokine receptor ligands
AU2002311841A1 (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
US7947720B2 (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040147559A1 (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1551818A1 (en) Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
WO2005066147A1 (en) Thiadiazoles as cxc- and cc- chemokine receptor ligands
US20040097547A1 (en) 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1697354A1 (en) Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
HK1057538B (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
HK1107818B (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): SCHERING CORPORATION; PHARMACOPEIA, INC.

Owner name: PHARMACOPEIA DRUG DISCOVERY, INC., US

Free format text: OLD OWNER(S): SCHERING CORPORATION; PHARMACOPEIA, INC.

RENW Renewal (renewal fees accepted)
PSEA Patent sealed
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): SCHERING CORPORATION; PHARMACOPEIA DRUG DISCOVERY, INC.

Owner name: PHARMACOPEIA, INC., US

Free format text: OLD OWNER(S): SCHERING CORPORATION; PHARMACOPEIA DRUG DISCOVERY, INC.

RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): SCHERING CORPORATION; PHARMACOPEIA, INC.

ASS Change of ownership

Owner name: SCHERING CORPORATION, US

Free format text: OLD OWNER(S): SCHERING CORPORATION

Owner name: PHARMACOPEIA, LLC, US

Free format text: OLD OWNER(S): SCHERING CORPORATION

RENW Renewal (renewal fees accepted)
LAPS Patent lapsed